Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy

Diseases of the Esophagus

Volumn 18, Issue 4, 2005, Pages 246-252

  Abdel Latif, Mohamed M M ^a   O'Riordan, J M ^a   Ravi, N ^a   Kelleher, D ^a   Reynolds, J V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Cytokines; Esophageal cancer; Neoadjuvant chemoradiotherapy; NF B

Indexed keywords

CISPLATIN; CYTOKINE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; INTERLEUKIN 1;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; EXPLORATORY RESEARCH; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; SQUAMOUS EPITHELIUM; STATISTICAL SIGNIFICANCE; TISSUE HOMOGENATE; TUMOR BIOPSY; TUMOR REGRESSION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOPSY; COMPARATIVE STUDY; EPITHELIUM; ESOPHAGUS; ESOPHAGUS TUMOR; FEMALE; MALE; PATHOLOGY; RADIATION DOSE; REMISSION;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOWN-REGULATION; EPITHELIUM; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGUS; FEMALE; FLUOROURACIL; HUMANS; INTERLEUKIN-1; INTERLEUKIN-8; MALE; NEOADJUVANT THERAPY; NF-KAPPA B; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION;

EID: 33644791331     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2005.00497.x     Document Type: Article

References (34)

1. Blot W J, Devesa S S, Kneller R W, Fraumeni J F Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J Am Med Assoc 1991; 265:1287-9.
2. Pera M, Cameron A, Trastek V, Carpenter H, Zermeister A. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-3.
3. Menke-Pluymers M B E, Schoute N W, Mulder A H, Hop W C, van Blankenstein M, Tilanus H W. Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus. Gut 1992; 33: 1454-8.
4. Parker S L, Tong T. Cancer statistics. CA Cancer J Clin 1997; 47: 5-27.
5. Walsh T N, Noonan N, Hollywood D, Kelly A, Keeling P W N, Hennessey T P J. A comparison of multimodel therapy and surgery for esophageal adenocarcinoma. New Engl J Med 1996; 335: 462-7.
6. Waters J S, Norman A, Cunningham D et al. Long term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of randomized trial. Br J Cancer 1999; 80: 269-72.
7. Andersen A P, Berdal P, Edsmyr F et al. Irradiation, chemotherapy and surgery in oesophageal cancer: A randomised clinical study. The first Scandinvian trial in oesophageal cancer. Radiother Oncol 1984; 2: 179-88.
8. Baeuerle P A, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994; 12: 141-79.
9. Kopp E B, Ghosh S. NF-κB and Rel proteins in innate immunity. Adv Immunol 1995; 58: 1-27.
10. Lind D S, Hochwald S N, Malaty J et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 2001; 130: 363-9.
11. Sovak M A, Bellas R E, Kim D W et al. Aberrant NF-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100: 2952-60.
12. Mori N, Fujii M, Ikeda S et al. Constitutive activation of NF-κB in primary adult leukemia cells. Blood 1999; 93: 2360-8.
13. Nakshatri H, Bhat-Nakshatri P, Martin D A, Goulet R J Jr, Sledge G W Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone independent growth. Mol Cell Biol 1997; 17: 3629-39.
14. Schmitt C A, Lowe S W. Apoptosis and therapy. J Pathol 1999; 187: 127-37.
15. Kastan M B. Molecular determinants of sensitivity to antitumor agents. Biochim Biophys Acta 1999; 1424: R37-42.
16. Hochwald S N, Lind D S, Malaty J, Copeland E M 3rd, Moldawer L L, MacKay S L. Anti-neoplastic therapy in colorectal cancer through proteasome inhibition. Am Surg 2003; 69: 15-23.
17. Wang C, Cusak J C, Liu R, Baldwin A S. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999; 5: 412-7.
18. Camp E R, Li J, Minnich D J et al. Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004; 199: 249-58.
19. Uetsuka H, Haisa M, Kimura M et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003; 289: 27-35.
20. Abdel-Latif M M, O'Riordan J, Windle H J et al. NF-kappaB activation in esophageal adenocarcinoma: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004; 239: 491-500.
21. Blackwell T S, Christman J W. The role of nuclear factor-κB in cytokine gene regulation. Am J Respiratory Cell Mol Biol 1997; 17: 3-9.
22. O'Riordan J, Abdel-Latif M M M, McNamara D et al. Cytokine and NF-kappaB profiles in the metaplasia-dysplasia-adenocarcinoma sequence in the oesophagus. Br J Surg 2003; 90: 611-2 (Abstract).
23. Schlemper R J, Riddell R H, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5.
24. Madrigal L, Lynch S, Feighery C, Weir D, Kelleher D, O'Farrelly C. Flow cytometric analysis of surface major histocompatibility complex class II expression on human epithelial cells prepared from small intestinal biopsies. J Immunol Methods 1993; 158: 207-14.
25. Osborn L, Kunkel S, Nabel G J. Tumour necrosis factor alpha and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor-kappa B. Pro Natl Acad Sci 1989; 86: 2336-40.
26. Bradford M M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
27. Bessell J R, Devitt P G, Gill P G, Goyal S, Jamieson G G. Prolonged survival follows resection of oesophageal SCC down-staged by prior chemoradiotherapy. Aust NZ J Surgery 1996; 66: 214-7.
28. Vogel S B, Mendenhall W M, Sombeck M D, Marsh R, Woodward E R. Down-staging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995; 221: 685-95.
29. Brach M A, Hass R, Sherman M L, Gunji H, Weichselbaum R, Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor-kappa B. J Clin Invest 1991; 88: 691-5.
30. Cataldi A, Rapino M, Centurione L et al. NF-kappaB activation plays an antiapoptotic role in human leukemic K562 cells exposed to ionizing radiation. J Cell Biochem 2003; 89: 956-63.
31. Wang C-Y, Mayo M W, Baldwin A S. TNF-α and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 1996; 274: 784-7.
32. Jung M, Dritschilo A. NF-kappa B signaling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol 2001; 11: 346-51.
33. McDonnell C O, Harmey J H, Bouchier-Hayes D J, Walsh T N. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. Br J Sur 2001; 88: 1105-9.
34. Cusack J C. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003; 29: 21-31.